Tyco reaches agreement to acquire Visonic

Tyco International Ltd. (NYSE: TYC) announced today that it has reached an agreement to acquire Visonic Ltd. (TASE: VSC.TA), a global developer and manufacturer of electronic security systems and components, for approximately $100 million in cash. The acquisition will strengthen the wireless product and technology portfolio and market presence of the Tyco Security Products business in the intrusion security market.

Visonic is a leader in developing advanced wireless technology for the security industry.  The company's recently introduced PowerG wireless communications technology offers increased communications range and superior 128-bit encryption to secure communication between wireless sensors/detectors and panels. The PowerG technology builds on Visonic's PowerCode technology which is in use in more than 1 million wireless installations around the world. The business has annualized revenues of more than $75 million.

"The acquisition of Visonic strengthens the technology capabilities in our intrusion security portfolio and will enable us to enhance the solutions we can offer to our residential and commercial customers," said Mark VanDover, President of Tyco Security Products. "Visonic is an established leader in wireless security technology and its strong presence in the European security market complements Tyco's strength in the North American market."

Visonic operates a state-of-the-art design center at its headquarters in Tel Aviv, Israel, as well as a manufacturing center in Kiryat Gat, Israel. The company is active in more than 100 countries, with a strong presence in Europe, Middle East and Africa.

The transaction is expected to close later this year and is subject to customary closing conditions.

Source:

Tyco International Ltd.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024